Meeting
2019 ASCO Annual Meeting
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.
Authors
Jonathan R. Strosberg
Moffitt Cancer Center, Tampa, FL
Jonathan R. Strosberg , Edward M. Wolin , Beth A. Chasen , Matthew H. Kulke , David L Bushnell Jr., Martyn Caplin , Richard P. Baum , Timothy J. Hobday , Andrew Eugene Hendifar , Paola Santoro , Per Broberg , Arnaud Demange , Kjell E. Oberg , Philippe B. Ruszniewski , Laura Ravasi , Eric Krenning
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4111)
DOI
10.1200/JCO.2019.37.15_suppl.4111
Abstract #
4111
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.
First Author: Jonathan R. Strosberg
Poster
2018 ASCO Annual Meeting
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2012 Gastrointestinal Cancers Symposium
Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors.
First Author: Tibor Gyökeres
Poster
2021 ASCO Annual Meeting
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg